Literature DB >> 31871299

Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models.

René Bruno1, Dean Bottino2, Dinesh P de Alwis3, Antonio T Fojo4, Jérémie Guedj5, Chao Liu6, Kristin R Swanson7, Jenny Zheng8, Yanan Zheng9, Jin Y Jin10.   

Abstract

There is a need for new approaches and endpoints in oncology drug development, particularly with the advent of immunotherapies and the multiple drug combinations under investigation. Tumor dynamics modeling, a key component to oncology "model-informed drug development," has shown a growing number of applications and a broader adoption by drug developers and regulatory agencies in the past years to support drug development and approval in a variety of ways. Tumor dynamics modeling is also being investigated in personalized cancer therapy approaches. These models and applications are reviewed and discussed, as well as the limitations and issues open for further investigations. A close collaboration between stakeholders like clinical investigators, statisticians, and pharmacometricians is warranted to advance clinical cancer therapeutics. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31871299     DOI: 10.1158/1078-0432.CCR-19-0287

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study.

Authors:  Kenta Yoshida; Phyllis Chan; Mathilde Marchand; Rong Zhang; Benjamin Wu; Marcus Ballinger; Nitzan Sternheim; Jin Y Jin; René Bruno
Journal:  AAPS J       Date:  2022-04-28       Impact factor: 4.009

2.  Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.

Authors:  Benjamin M Ellingson; Elizabeth R Gerstner; Andrew B Lassman; Caroline Chung; Howard Colman; Patricia E Cole; David Leung; Joshua E Allen; Manmeet S Ahluwalia; Jerrold Boxerman; Matthew Brown; Jonathan Goldin; Edjah Nduom; Islam Hassan; Mark R Gilbert; Ingo K Mellinghoff; Michael Weller; Susan Chang; David Arons; Clair Meehan; Wendy Selig; Kirk Tanner; W K Alfred Yung; Martin van den Bent; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2022-08-01       Impact factor: 13.029

3.  Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel.

Authors:  Sreenath M Krishnan; Sofiene S Laarif; Brendan C Bender; Angelica L Quartino; Lena E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-02

4.  Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.

Authors:  Hoai-Thu Thai; Nadia Gaudel; Marc Cerou; Geraldine Ayral; Jean-Baptiste Fau; Bernard Sebastien; Helgi van de Velde; Dorothée Semiond; Christine Veyrat-Follet
Journal:  Br J Clin Pharmacol       Date:  2021-11-26       Impact factor: 3.716

Review 5.  Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects.

Authors:  Haiqing Isaac Dai; Yulia Vugmeyster; Naveen Mangal
Journal:  Clin Pharmacol Ther       Date:  2020-08-02       Impact factor: 6.875

6.  Application of Machine Learning for Tumor Growth Inhibition - Overall Survival Modeling Platform.

Authors:  Phyllis Chan; Xiaofei Zhou; Nina Wang; Qi Liu; René Bruno; Jin Y Jin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-13

7.  Targeting Cellular DNA Damage Responses in Cancer: An In Vitro-Calibrated Agent-Based Model Simulating Monolayer and Spheroid Treatment Responses to ATR-Inhibiting Drugs.

Authors:  Sara Hamis; James Yates; Mark A J Chaplain; Gibin G Powathil
Journal:  Bull Math Biol       Date:  2021-08-30       Impact factor: 1.758

8.  Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.

Authors:  Michael L Maitland; Julia Wilkerson; Sanja Karovic; Binsheng Zhao; Jessica Flynn; Mengxi Zhou; Patrick Hilden; Firas S Ahmed; Laurent Dercle; Chaya S Moskowitz; Ying Tang; Dana E Connors; Stacey J Adam; Gary Kelloff; Mithat Gonen; Tito Fojo; Lawrence H Schwartz; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 12.531

9.  Deep Learning Approaches to Surrogates for Solving the Diffusion Equation for Mechanistic Real-World Simulations.

Authors:  J Quetzalcóatl Toledo-Marín; Geoffrey Fox; James P Sluka; James A Glazier
Journal:  Front Physiol       Date:  2021-06-24       Impact factor: 4.566

10.  Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel.

Authors:  Sreenath M Krishnan; Lena E Friberg; René Bruno; Ulrich Beyer; Jin Y Jin; Mats O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.